Drug Profile

Research programme: parathyroid hormone 1 receptor antagonists - Theratechnologies

Alternative Names: TH 1303; THG 1303; THG 1305

Latest Information Update: 01 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

25 Sep 2025 Theratechnologies has been acquired by CB Biotechnology
14 Sep 2004 Data presented at the 86^th Annual Meeting of the Endocrine Society (ENDO-2004) have been added to the Endocrine Disorders pharmacodynamics section
05 Jul 2004 Preclinical trials in Hyperparathyroidism in Canada (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com